Targets › PDE
2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 2; Other, Genitourinary; next expected readout Oct 2027.
Open in Phaseline: the race on PDE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Western Galilee Hospital-Nahariya | Papaverine Phosphodiesterase inhibitor; non-selective vasodilator | PDE | Phase 4 | Premature Rupture of Membranes | Oct 2027 |
| Prokrea BCN | PKB171 Phosphodiesterase inhibitor (pentoxifylline); increases sperm motility and peripheral bloo | PDE | Phase 2 | Infertility Due to Azoospermia | Oct 2027 |
Premature Rupture of Membranes (1) Infertility Due to Azoospermia (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.